Bubendorf, Switzerland, January 2016 — Proof of concept studies at NBE Therapeutics demonstrated conjugation of CIS Pharma’s Cellophil® Smart Polymer drug carrier to antibodies. Consequently, different linkers were evaluated for loading the drug carrier with anti-cancer moieties. CIS Pharma has successfully loaded its proprietary Cellophil® Smart Polymer drug carriers with model compounds for cancer therapies. CIS Pharma engineers the ADCs to deliver anti-cancer agents to cancerous cells. The Cellophil® drug carrier and the linkers used are targeting control over when, where and how the cytotoxins are released.

About antibody-drug conjugates

Antibody-drug conjugates, or ADCs, are a class of highly potent drugs for the treatment of cancer. ADCs are composed of an antibody that is linked to an anti-cancer payload. The conjugates target cancer cells. Due to the high affinity of the antibodies to tumor cells, the cytotoxic payload is delivered specifically to the cancer tissue, reducing harmful side effects associated with traditional chemotherapeutic agents.

About CIS Pharma AG

CIS Pharma AG is an innovator in the life science industry. The company was founded in 1952 and is family owned. CIS Pharma is located in the life science cluster of Basel, Switzerland. In our laboratories, we synthesize novel molecules, develop new biomaterials and create cutting-edge medical devices. Our mission is to improve the risk-benefit profile of currently used medical treatments. For more information about the company, visit our website www.cis-pharma.com. — Discovery is our business, progress our passion.